Tutorials
|
|
|
|
.
|
Hoeks
CM, Barentsz JO, Hambrock T, Yakar D, Somford DM, Heijmink SW,
Scheenen TW, Vos PC, Huisman H, van Oort IM, Witjes JA, Heerschap
A, Fütterer JJ
Prostate
cancer: multiparametric MR imaging for detection, localization,
and staging.
Radiology.
2011 Oct;261(1):46-66. doi: 10.1148/radiol.11091822.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Jin K, Qiu S, Li J, Zheng X, Tu X, Liao X, Yang Y, Yang L, Wei Q.
How to choose proper local treatment in men aged ≥75
years with cT2 localized prostate cancer?
Cancer Med.
2019 Jul;8(7):3370-3378. doi: 10.1002/cam4.2221. Epub 2019 May 8.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Simmons MN, Berglund RK, Jones JS.
A practical
guide to prostate cancer diagnosis and management.
Cleve
Clin J Med. 2011 May;78(5):321-31. doi: 10.3949/ccjm.78a.10104.
Source
| Full
text |
Similar
articles
|
|
|
DECISION
CURVE ANALYSIS
|
|
.
|
Van Calster B, Wynants L, Verbeek JFM, Verbakel JY, Christodoulou
E, Vickers AJ, Roobol MJ, Steyerberg EW.
Reporting and
Interpreting Decision Curve Analysis: A Guide for Investigators.
Eur Urol. 2018 Sep 19. pii: S0302-2838(18)30640-7. doi:
10.1016/j.eururo.2018.08.038. [Epub ahead of print]
Source
| Full
text |
Similar
articles
|
|
|
Opinions
|
|
.
|
Schulman
AA, Polascik TJ.
Most
of patients with localized prostate cancer will be treated in the
future? | Opinion: No.
Int
Braz J Urol. 2017 Jul-Aug;43(4):584-587. doi:
10.1590/S1677-5538.IBJU.2017.04.03.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Dell'Oglio
P, Sanchez-Salas R.
Most
of patients with localized prostate cancer will be treated in the
future? | Opinion: Yes.
Int
Braz J Urol. 2017 Jul-Aug;43(4):579-583. doi:
10.1590/S1677-5538.IBJU.2017.04.02.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Tosoian JJ, Carter HB.
Patients with Intermediate Risk
Prostate Cancer May be Good Candidates for Active Surveillance:
Con.
J Urol. 2017 Sep 22. pii: S0022-5347(17)77388-0.
doi: 10.1016/j.juro.2017.08.088. [Epub ahead of print]
Source
| Full
text |
Similar
articles
|
|
|
.
|
Sanda MG.
Patients with Intermediate Risk Prostate Cancer
May be Good Candidates for Active Surveillance: Pro.
J
Urol. 2017 Sep 22. pii: S0022-5347(17)77389-2. doi:
10.1016/j.juro.2017.08.089. [Epub ahead of print]
Source
| Full
text |
Similar
articles
|
|
|
RADIOTHERAPY
|
|
|
|
ADJUVANT
RADIOTHERAPY
|
|
|
|
High-Risk
Prostate Cancer
|
|
.
|
Tendulkar R.
Point: Early Salvage vs Adjuvant
Radiotherapy for High-Risk Prostate Cancer.
Oncology
(Williston Park). 2017 Oct 15;31(10):750-2.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Wu WJ, Potters L.
Counterpoint: Early Salvage vs Adjuvant
Radiotherapy for High-Risk Prostate Cancer.
Oncology
(Williston Park). 2017 Oct 15;31(10):750, 752-4.
Source
| Full
text |
Similar
articles
|
|
|
SURGERY
|
|
.
|
Cooperberg MR.
How Should a Man with Prostate Cancer
Choose his Surgeon?
Eur Urol. 2018 Feb 3. pii:
S0302-2838(18)30074-5. doi: 10.1016/j.eururo.2018.01.020. [Epub
ahead of print]
Source
| Full
text |
Similar
articles
|
|
|
Comments
|
|
.
|
Baker SG.
Validity of Surrogate End Points for Prostate
Cancer.
JAMA Oncol. 2017 Aug 31. doi:
10.1001/jamaoncol.2017.0334. [Epub ahead of print]
Source
| Full
text | Similar
articles
|
|
|
.
|
D'Amico
AV.
Active
Surveillance Versus Treatment of Prostate Cancer: Should
Metastasis Be the Primary End Point?
J
Clin Oncol. 2017 Feb 27:JCO2016709527. doi:
10.1200/JCO.2016.70.9527. [Epub ahead of print]
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Hartzband
P, Groopman J.
There
is more to life than death.
N
Engl J Med. 2012 Sep 13;367(11):987-9. doi: 10.1056/NEJMp1207052.
Source
|
Full
text |
Similar
articles
|
|
|
|
Royce TJ, Chen MH, D'Amico AV.
Validity of Surrogate End
Points for Prostate Cancer-Reply.
JAMA Oncol. 2017 Aug
31. doi: 10.1001/jamaoncol.2017.2506. [Epub ahead of print]
Source
| Full
text | Similar
articles
|
|
|
.
|
Royce TJ, Chen MH, Wu J, Loffredo M, Renshaw AA, Kantoff PW,
D'Amico AV.
Surrogate End Points for All-Cause Mortality
in Men With Localized Unfavorable-Risk Prostate Cancer Treated
With Radiation Therapy vs Radiation Therapy Plus Androgen
Deprivation Therapy: A Secondary Analysis of a Randomized Clinical
Trial.
JAMA Oncol. 2017 May 1;3(5):652-658. doi:
10.1001/jamaoncol.2016.5983.
Source
| Full
text | Similar
articles
|
|
|
.
|
Wilt
TJ, LeFevre M; U.S. Preventive Services Task Force.
There
is more to life than death.
N
Engl J Med. 2012 Dec 6;367(23):2258-9; author reply 2259-60. doi:
10.1056/NEJMc1212298#SA1.
Comment
on: Hartzband P, Groopman J., There is more to life than death [N
Engl J Med. 2012 Sep 13]
Source
|
Full
text |
Similar
articles
|
|
|
NEWS
|
|
.
|
Kapoor
A.
What's
new in prostate cancer research?
Can
Urol Assoc J. 2016 May-Jun;10(5-6Suppl2):S127-S129.
Source
|
Full
text |
Similar
articles
|
|
|
DOSE-ESCALATED
RADIOTHERAPY
|
|
.
|
Dalela
D, Karabon P, Abdollah F.
Androgen
Deprivation Therapy and Dose-Escalated Radiotherapy for
Intermediate- and High-Risk Prostate Cancer: Sign of Changing
Times?
JAMA
Oncol. 2016 Nov 23. doi: 10.1001/jamaoncol.2016.3987. [Epub ahead
of print]
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Falchook
AD, Basak R, Chen RC.
Androgen
Deprivation Therapy and Dose-Escalated Radiotherapy for
Intermediate- and High-Risk Prostate Cancer-Reply.
JAMA
Oncol. 2016 Nov 23. doi: 10.1001/jamaoncol.2016.3974. [Epub ahead
of print]
Source
|
Full
text |
Similar
articles
|
|
|
Perspectives
|
|
.
|
Freedland SJ.
20 years-A retrospective of prostate cancer
and prostatic diseases.
Prostate Cancer Prostatic Dis.
2017 Dec 19. doi: 10.1038/s41391-017-0025-6. [Epub ahead of print]
Source
| Full
text |
Similar
articles
|
|
|
|
|
